

BRAIN Biotech AG

Creating a #BiobasedFuture

Management Statement 6M FY 2023/24

Adriaan Moelker, CEO

Michael Schneiders, CFO

Zwingenberg, May 28th, 2024

WE SUPPORT



Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.



Safe Harbor Statement

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

This presentation speaks as of May 28th, 2024. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The term "BRAIN", as used in this presentation means BRAIN Biotech AG and its affiliates, if not otherwise specified.

Business Highlights 6M FY 2023/24

major pharma milestone received, accelerating products business, improved cash position

➤ **Deucricitibant licensed to Pharvaris**

- Milestone payment received with gross proceeds of EUR 1.5 million, highest ever in company history
- Phase 3 trials entered, significantly increasing overall project probability with corresponding milestone payments and royalties on future sales

➤ **BioProducts**

- Breatec continues on a very strong growth path
- Accelerating momentum BioProducts Q2 over Q1
- Further acceleration expected in H2

➤ **Cash on hand**

- Cash position almost doubled from Q1 to EUR 10.2 million
 - cash inflow from increasing financial liabilities: EUR 5.5 million
 - payment received for the convertible bonds issued: EUR 5.0 million
 - scheduled repayments: EUR 1.8 million

Business Highlights 6M FY 2023/24

BioIncubator projects with good progress

➤ **Gold from Waste streams**

- Project progresses as planned
- BioXtractor hauled from Zwingenberg Campus to partner location
- Now integrated in production process at partner site

➤ **Brazzein**

- Good progress in the project with a new, strong partner
- Constructive negotiations on commercialization
- Brazzein now FDA GRAS approved in the US

➤ **Industrial-scale producer strains**

- BRAIN keeps successfully investing in this platform technology as a key driver of the bio-economy
- Major milestones were hit and exceeded in partner programs and against internal benchmarks
- Increasing productivity and fermentation service portfolio at Biocatalysts
- Building-up a future licensing business for third parties
- Strongly tied to TMS+ strategy

Financial Highlights 6M FY 2023/24 at a Glance

major milestone income in BioIncubator – BioProducts growth accelerating

(in € thousand)	6M 2023/24	6M 2022/23	Growth	Organic Growth	Q2 2023/24	Q2 2022/23	Growth	Organic Growth	Comment
Revenues	27.204	27.170	0,1%	0,1%	14.474	13.476	7,4%	7,4%	
BioProducts	19.819	20.853	-5,0%	-5,0%	10.499	10.217	2,8%	2,8%	
BioScience	5.822	6.145	-5,3%	-5,3%	2.462	2.992	-17,7%	N/A	Milestones €140k 6M 23/24 Milestones €55k 6M 22/23
BioIncubator	1.602	175	815,3%	N/A	1.533	87,5	1651,7%	N/A	Pharvaris Milestone €1,500k +Akribion License & TMS Sales
Total operating performance (1)	27.357	28.093	-2,6%	N/A	14.280	14.596	-2,2%	N/A	
Adjusted EBITDA (2)	-481	-915	47,4%	N/A	176	-528	133,3%	N/A	(-) €432K ESOP 6M FY23/24 (-) €434K ESOP 6M FY22/23
EBITDA	-913	-1.349	32,3%	N/A	-23	-646	96,4%	N/A	
EBIT	-3.253	-3.565	8,7%	N/A	-1.184	-1.754	32,5%	N/A	
Net Result	-4.605	-4.608	0,1%	N/A	-1.973	-2.152	8,3%	N/A	
Operating Cash Flow	-3.186	-5.557	42,7%	N/A	-539	-3.513	84,7%	N/A	
	31.03.2024	30.09.2023							
Cash	10.170	5.352	90,0%	90,0%					

	6M 23/24	6M 22/23	Growth	Organic Growth
Number of Employees (3)	311	309	0,6%	0,6%
Material Expense Ratio	41,0%	47,8%	- 6.8% PP.	- 6.8% PP.
Adj. Personnel Expense Ratio	42,9%	40,3%	2.6% PP.	2.6% PP.

Major Events 6M '23/24:

- **BioProducts** acceleration Q2 over Q1, strong H2 expected; high growth momentum especially at Breatac
- **BioScience** satisfactory H1; still expect growth for the full year; especially revenue recognition of library sales remains volatile Q by Q
- **BioIncubator** with EUR 1.5 million gross deucriticant milestone from Pharvaris; additional license revenue from Akribion Genomics activities
- **Adjusted EBITDA**, only adjustments for ESOP of € -432k, on the level of last year

➤ Akribion Genomics gross investments
@ 6M ~ € 1.5 million (6M LY ~ € 1.7 million, timing)

(1) Revenues + change in inventories + other income + R&D grants

(2) The full reconciliation from adjusted to unadjusted EBITDA can be found in the quarterly report

(3) Excluding Board members, managing directors, temporary staff, students and trainees

Cash & Cash Flow


cash position significantly strengthened; all financing measures successfully executed

(in € thousand)	6M 2023/24	6M 2022/23	Growth	Q2 2023/24	Q2 2022/23	Growth	Comment
Gross Cash Flow	-4,370	-2,798	-56.2%	-1,134	-1,228	7.7%	
Operating Cash Flow	-3,186	-5,557	42.7%	-539	-3,513	84.7%	
Investing Cash Flow	-729	1,693	-143.1%	-344	-678	49.3%	Divestment of L.A.Schmitt €3 mio in 3M 22/23
Financing Cash Flow	8,704	4,607	88.9%	6,537	2,556	155.8%	
Net change in Cash & Cash Equivalents	4,789	743	544.6%	5,654	-1,636	445.7%	
	31.03.2024	30.09.2023					
Cash	10,170	5,352	90.0%				
Equity	19,605	23,013	-14.8%				

- Cash on hand almost doubled versus 12M
- Additional financing initiatives for FY 23/24:
 - € 5 million non-dilutive financing: silent participation Hessen Kapital, € 4.1 million net cash-in realized Q3
 - additional non-dilutive measures with reach beyond 23/24 in negotiations

Adjusted EBITDA

keeping up well despite lower Q1 sales contribution thanks to strong cost discipline and milestones



Milestones and strong cost discipline

- **BioScience:** weaker Q2 after strong Q1; high cost discipline reflected in flat adjusted EBITDA
- **BioProducts:** lower adj. EBITDA driven by low Q1 sales, mix effects and second large-scale fermenter teething problems throughout H1
- **BioIncubator:** strong milestone income, flat expensed investments for Akribion Genomics as also guided for full year
- **Holding:** mild cost increase despite high service cost inflation, strong overall cost control maintained

- Akribion Genomics gross investments @ 6M ~ € 1.5 million (1.7 million LY, timing)
- Still teething issues of second large-scale fermenter in H1, now successfully commissioned

Our Targets

FY Guidance and Mid-Term Targets

This FY Guidance

Quantitative Guidance

Group sales: € 58 to 62 million

- BioProducts and BioScience both contributing

Adj. EBITDA

- to improve at least in-line with revenue development

Akribion Genomics

- associated expensed investments: ~ € 3.3 million (flat YoY)

Group CAPEX

- € 3 - 4 million

(as far as this guidance is concerned any changes in the consolidation scope are considered separately and do not form part of this forecast)

Mid-Term Targets - Unchanged

(issued 02/23; 4-6 year targets)

(excluding Akribion Genomics)

€ 100 million group revenues

- Double digit topline product CAGR on average
- Accretive bolt-on M&A
- Contract research, TMS, low single digit growth (excluding milestones and royalties)

Group adj. EBITDA margin 15% (+/- 5PP)

- Double digit fermentation production volume of customized novel enzymes
- Mid-single digit annual productivity improvements & synergies

Proportion of new product sales: ~30% of product revenues

- Continuous innovation pipeline management

General Risk Factor Update

ongoing business risk monitoring

Summary:

BRAIN Group: overall business growth remains solid despite a challenging overall macroeconomic environment. Inflationary pressures still present and require ongoing monitoring. Geopolitical risks remain high. Second large-scale fermenter now ramped, adding production flexibility and growth potential.

Current Situation: Limited supply chain constraints still persist. Ongoing and volatile inflationary pressures on material, energy and especially labor costs with potential time-lag to pass-on. Stocking and de-stocking effects add to volatility. Tight labor market conditions across all geographies: war for talent.

Future Challenges: General business cycle risk with stagflation or recession as a possible scenario. US growth engine weakening. China slow recovery. Hence, European main export markets challenged. General consumption weakness. Geopolitical stress and risk remains high. High interest rates diminish general interest in growth assets. Refinancing conditions for start-ups and Biotech sector remain challenging.

Financial Calendar

2024/2025



HALFYEAR STATEMENT

Publication of the half year report as of March 31st, 2024 (6M)

May 28th, 2024



QUARTERLY STATEMENT

Publication of the quarterly statement as of June 30th, 2024 (9M)

August 29th, 2024



ANNUAL REPORT

Publication of the annual year report as of September 30th, 2024 (12M)

January 15th, 2025



QUARTERLY STATEMENT

Publication of the quarterly statement as of December 31st, 2024 (3M)

February 26th, 2025

Thank you very much for your interest.



BRAIN Biotech AG

Darmstädter Straße 34–36
64673 Zwingenberg, Germany

+49 (0) 6251-9331-0
www.brain-biotech.com

Your contacts:

Michael Schneiders, CFO
+49 (0) 6251-9331-86
MiS@brain-biotech.com

Martina Schuster, IR
+49 (0) 6251-9331-69
MS@brain-biotech.com

 @BRAINbiotechAG

 BRAIN AG

 BRAIN Biotech AG